|
1
|
Jung KW, Park S, Kong HJ, et al: Cancer
statistics in Korea: incidence, mortality and survival in
2006–2007. J Korean Med Sci. 25:1113–1121. 2010.
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Owonikoko TK, Ragin CC, Belani CP, et al:
Lung cancer in elderly patients: an analysis of the surveillance,
epidemiology, and end results database. J Clin Oncol. 25:5570–5577.
2007. View Article : Google Scholar
|
|
4
|
Sher T, Dy GK and Adjei AA: Small cell
lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar
|
|
5
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003.
|
|
6
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Addition of platinum compounds to a new
agent in patients with advanced non-small-cell lung cancer: a
literature based meta-analysis of randomised trials. Ann Oncol.
15:1782–1789. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Laskin JJ and Sandler AB: Epidermal growth
factor receptor: a promising target in solid tumours. Cancer Treat
Rev. 30:1–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosell R, Moran T, Queralt C, et al:
Screening for epidermal growth factor receptor mutations in lung
cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bean J, Brennan C, Shih JY, et al:
MET amplification occurs with or without T790M
mutations in EGFR mutant lung tumors with acquired
resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA.
104:20932–20937. 2007. View Article : Google Scholar
|
|
14
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar
|
|
15
|
Yano S, Wang W, Li Q, et al: Hepatocyte
growth factor induces gefitinib resistance of lung adenocarcinoma
with epidermal growth factor receptor-activating mutations. Cancer
Res. 68:9479–9487. 2008. View Article : Google Scholar
|
|
16
|
Sequist LV, Waltman BA, Dias-Santagata D,
et al: Genotypic and histological evolution of lung cancers
acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Engelman JA, Zejnullahu K, Gale CM, et al:
PF00299804, an irreversible pan-ERBB inhibitor, is effective in
lung cancer models with EGFR and ERBB2 mutations that
are resistant to gefitinib. Cancer Res. 67:11924–11932. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Z, Du R, Jiang S, et al: Dual
MET-EGFR combinatorial inhibition against T790M-EGFR-mediated
erlotinib-resistant lung cancer. Br J Cancer. 99:911–922. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saha SK and Khuda-Bukhsh AR: Molecular
approaches towards development of purified natural products and
their structurally known derivatives as efficient anti-cancer
drugs: current trends. Eur J Pharmacol. 714:239–248. 2013.
View Article : Google Scholar
|
|
20
|
Youn HJ, Lakritz J, Kim DY, Rottinghaus GE
and Marsh AE: Anti-protozoal efficacy of medicinal herb extracts
against Toxoplasma gondii and Neospora caninum. Vet
Parasitol. 116:7–14. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong SW, Jung KH, Lee HS, et al: SB365
inhibits angiogenesis and induces apoptosis of hepatocellular
carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Cancer Sci. 103:1929–1937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong SW, Jung KH, Lee HS, et al: SB365,
Pulsatilla saponin D, targets c-Met and exerts
antiangiogenic and antitumor activities. Carcinogenesis.
34:2156–2169. 2013.PubMed/NCBI
|
|
23
|
Son MK, Jung KH, Hong SW, et al: SB365,
Pulsatilla saponin D suppresses the proliferation of human
colon cancer cells and induces apoptosis by modulating the AKT/mTOR
signalling pathway. Food Chem. 136:26–33. 2013.PubMed/NCBI
|
|
24
|
Son MK, Jung KH, Lee HS, et al: SB365,
Pulsatilla saponin D suppresses proliferation and induces
apoptosis of pancreatic cancer cells. Oncol Rep. 30:801–808.
2013.PubMed/NCBI
|
|
25
|
Kim Y, Bang SC, Lee JH and Ahn BZ:
Pulsatilla saponin D: the antitumor principle from
Pulsatilla koreana. Arch Pharm Res. 27:915–918. 2004.
View Article : Google Scholar
|
|
26
|
Ghosh G, Yan X, Lee AG, Kron SJ and
Palecek SP: Quantifying the sensitivities of EGF receptor (EGFR)
tyrosine kinase inhibitors in drug resistant non-small cell lung
cancer (NSCLC) cells using hydrogel-based peptide array. Biosens
Bioelectron. 26:424–431. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Freedman VH and Shin SI: Cellular
tumorigenicity in nude mice: correlation with cell growth in
semi-solid medium. Cell. 3:355–359. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao J: Nutraceuticals, nutritional
therapy, phytonutrients, and phytotherapy for improvement of human
health: a perspective on plant biotechnology application. Recent
Pat Biotechnol. 1:75–97. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taylor WG, Elder JL, Chang PR and Richards
KW: Micro-determination of diosgenin from fenugreek (Trigonella
foenum-graecum) seeds. J Agric Food Chem. 48:5206–5210. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Price KR, Johnson IT and Fenwick GR: The
chemistry and biological significance of saponins in foods and
feedingstuffs. Crit Rev Food Sci Nutr. 26:27–135. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jeong CH, Bode AM, Pugliese A, et al:
[6]-Gingerol suppresses colon cancer growth by targeting
leukotriene A4 hydrolase. Cancer Res. 69:5584–5591.
2009.
|
|
32
|
Oi N, Jeong CH, Nadas J, et al:
Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by
inhibiting leukotriene A4 hydrolase. Cancer Res.
70:9755–9764. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jung SK, Lee KW, Byun S, et al: Myricetin
inhibits UVB-induced angiogenesis by regulating PI-3 kinase in
vivo. Carcinogenesis. 31:911–917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi
Y, Vande Woude GF and Testa JR: Anti-apoptotic signaling by
hepatocyte growth factor/Met via the phosphatidylinositol
3-kinase/Akt and mitogen-activated protein kinase pathways. Proc
Natl Acad Sci USA. 98:247–252. 2001. View Article : Google Scholar : PubMed/NCBI
|
